RecruitingOverweightObesity

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Eligible age

18–75 yrs

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ See Master Protocol CWMM (NCT06143956) for inclusion criteria

You may not qualify if…

✕ In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):
✕ Have type 1 diabetes or type 2 diabetes
✕ Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
✕ Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
✕ Have a history of acute or chronic pancreatitis
✕ All concomitant medications should be at a stable dose for at least 3 months prior to screening